Edwards Lifesciences (EW) Tops Q1 EPS by 12c, Narrows FY 2017 Guidance

Edwards Lifesciences (NYSE: EW) reported Q1 EPS of $0.94, $0.12 better than the analyst estimate of $0.82. Revenue for the quarter came in at $883.5 million versus the consensus estimate of $777.83 million.

GUIDANCE:

Edwards Lifesciences sees Q2 2017 EPS of $0.82-$0.92. Edwards Lifesciences sees Q2 2017 revenue of $810-850 million.

Edwards Lifesciences raises FY 2017 EPS to $3.43-$3.55 from $3.30-3.45 . Edwards Lifesciences sees Q2 2017 revenue of $3.2-3.4 billion, narrowed from $3.0-3.4 billion.

"Our strong start to 2017 bolsters our confidence in our focused innovation strategy," said CEO Mussallem. "We believe there are abundant opportunities within our areas of focus to provide meaningful innovations for patients and drive significant organic growth. Our foundation of leadership, coupled with a robust product pipeline, positions us well for continued longer-term success and greater shareholder value."

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.

You May Also Be Interested In

• Procter & Gamble (PG) revenue falls short of expectations, raises full-year earnings guidance
• Super Micro Computer (SMCI) Falls 6%
• Vail Resorts (MTN) Reports Certain Ski Season Metrics for the Season-to-Date Period Ended April 14